Systematic Review of Compound Danshen Dropping Pill: A Chinese Patent Medicine for Acute Myocardial Infarction

Table 5

Analyses of primary outcomes.

Outcomes; (comparisons)	Treatment (𝑛/𝑁)	Control (𝑛/𝑁)	Weight; (%)	RR	95% CI
(1) All-cause mortality
(1.1) CDDP + conventional therapy versus conventional therapy
Guo et al. 2010 [20]	5/76	5/60	19.10	0.79	[0.24, 2.60]
Li et al. 2011 [19]	6/252	4/248	13.80	1.48	[0.42, 5.17]
Ma 2010 [35]	5/78	11/85	36.10	0.50	[0.18, 1.36]
Xu and Wang 2007 [21]	3/66	10/80	31.00	0.36	[0.10, 1.27]
Total (FEM, 𝐼^2 = 0%)			100.00	0.65	[0.37, 1.14]
Sensitive analysis
Guo et al. 2010 [20]	5/76	5/60	22.20	0.79	[0.24, 2.60]
Ma 2010 [35]	5/78	11/85	41.80	0.50	[0.18, 1.36]
Xu and Wang 2007 [21]	3/66	10/80	35.90	0.36	[0.10, 1.27]
Total (FEM, 𝐈^𝟐 = 0%)			100.00	0.51	[0.27, 0.98]
(1.2) CDDP + conventional therapy versus propranolol + conventional therapy
Xu and Wang 2007 [21]	3/66	5/72	100.00	0.65	[0.16, 2.63]
(2) Cardiac mortality
(2.1) CDDP + conventional therapy versus conventional therapy
Ma 2010 [35]	5/78	11/85	53.80	0.50	[0.18, 1.36]
Xu and Wang 2007 [21]	3/66	10/80	46.20	0.36	[0.10, 1.27]
Total (FEM, 𝐈^𝟐 = 0%)			100.00	0.43	[0.20, 0.95]
(2.2) CDDP + conventional therapy versus placebo + conventional therapy
Li et al. 2010 [36]	1/42	1/21	100.00	0.50	[0.03, 7.60]
(2.3) CDDP + conventional therapy versus propranolol + conventional therapy
Xu and Wang 2007 [21]	3/66	4/72	100.00	0.81	[0.17, 3.76]
(3) Recurrent myocardial infarction
(3.1) CDDP + conventional therapy versus conventional therapy
Xu and Wang 2007 [21]	2/66	8/80	100.00	0.30	[0.07, 1.38]
(3.2) CDDP + conventional therapy versus placebo + conventional therapy
Li et al. 2010 [36]	3/42	3/21	100.00	0.50	[0.11, 2.27]
(3.3) CDDP + conventional therapy versus propranolol + conventional therapy
Xu and Wang 2007 [21]	2/66	3/72	100.00	0.73	[0.13, 4.22]